|
Date Submitted:
12/11/07
Hits: 33 Rating:  0/5 based on 0 votes
Biologic Drug Approved to Prevent Hepatitis B in Liver Recipients
Description:
HepaGam B, a first-of-its-kind immune globulin product, has been approved by the U.S. Food and Drug Administration to prevent hepatitis B reinfection among people who have received liver transplants, the agency said Friday.
Read the Complete Article Similar content: Hepatitis C Infection May Not Always Lead to Chronic Liver Disease, in Hepatitis Hepatitis C Infection Hampers Liver Transplant Success, in Hepatitis Hepatitis B Drug Triggers HIV Drug Resistance, in Hepatitis Most Medicare Recipients Ignore Colorectal Cancer Screening, in Prostate Cancer New Hepatitis B Drug Better Than Others, in Hepatitis |
